ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
JERSEY CITY, N.J., Aug. 07, 2017 -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental Boston on Thursday, August 10, 2017 at 11:30 a.m. ET.
A live webcast will be available on the investors section of the Company’s website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel oral and intravenous triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
